TScan Therapeutics (TCRX) Competitors $2.40 -0.06 (-2.44%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends TCRX vs. VECT, KURA, TECX, CRGX, HUMA, ANNX, PHVS, KROS, MREO, and RAPPShould you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include VectivBio (VECT), Kura Oncology (KURA), Tectonic Therapeutic (TECX), CARGO Therapeutics (CRGX), Humacyte (HUMA), Annexon (ANNX), Pharvaris (PHVS), Keros Therapeutics (KROS), Mereo BioPharma Group (MREO), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry. TScan Therapeutics vs. VectivBio Kura Oncology Tectonic Therapeutic CARGO Therapeutics Humacyte Annexon Pharvaris Keros Therapeutics Mereo BioPharma Group Rapport Therapeutics VectivBio (NASDAQ:VECT) and TScan Therapeutics (NASDAQ:TCRX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, community ranking, institutional ownership, risk and dividends. Do analysts recommend VECT or TCRX? TScan Therapeutics has a consensus price target of $11.25, indicating a potential upside of 368.75%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than VectivBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VectivBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00TScan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is VECT or TCRX more profitable? VectivBio has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,188.88%. VectivBio's return on equity of 0.00% beat TScan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VectivBioN/A N/A N/A TScan Therapeutics -1,188.88%-58.72%-36.02% Do insiders & institutionals have more ownership in VECT or TCRX? 82.8% of TScan Therapeutics shares are held by institutional investors. 9.7% of VectivBio shares are held by insiders. Comparatively, 2.8% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher earnings & valuation, VECT or TCRX? TScan Therapeutics has lower revenue, but higher earnings than VectivBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVectivBio$27.34MN/A-$93.74MN/AN/ATScan Therapeutics$9.36M13.68-$89.22M-$1.06-2.26 Does the media prefer VECT or TCRX? In the previous week, TScan Therapeutics had 3 more articles in the media than VectivBio. MarketBeat recorded 3 mentions for TScan Therapeutics and 0 mentions for VectivBio. TScan Therapeutics' average media sentiment score of 0.55 beat VectivBio's score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment VectivBio Neutral TScan Therapeutics Positive Does the MarketBeat Community favor VECT or TCRX? TScan Therapeutics received 25 more outperform votes than VectivBio when rated by MarketBeat users. Likewise, 81.40% of users gave TScan Therapeutics an outperform vote while only 43.48% of users gave VectivBio an outperform vote. CompanyUnderperformOutperformVectivBioOutperform Votes1043.48% Underperform Votes1356.52% TScan TherapeuticsOutperform Votes3581.40% Underperform Votes818.60% SummaryTScan Therapeutics beats VectivBio on 9 of the 14 factors compared between the two stocks. Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRX vs. The Competition Export to ExcelMetricTScan TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$128.09M$2.96B$5.23B$8.96BDividend YieldN/A1.94%5.13%4.04%P/E Ratio-2.2644.8387.9117.30Price / Sales13.68265.291,258.3378.69Price / CashN/A192.9043.8235.97Price / Book0.763.965.324.79Net Income-$89.22M-$41.02M$122.78M$225.07M7 Day Performance-13.36%-1.80%-0.19%1.52%1 Month Performance-17.24%0.47%3.73%4.69%1 Year Performance-54.37%-1.73%27.32%20.91% TScan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRXTScan Therapeutics2.5696 of 5 stars$2.40-2.4%$11.25+368.8%-58.8%$128.09M$9.36M-2.26100News CoverageVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030KURAKura Oncology4.3237 of 5 stars$7.24-1.1%$27.38+278.1%-50.8%$563.01MN/A-3.07130Short Interest ↑TECXTectonic Therapeutic2.0414 of 5 stars$37.83-5.8%$72.25+91.0%N/A$558.11MN/A-6.42120Positive NewsCRGXCARGO Therapeutics1.5852 of 5 stars$12.04-10.8%$31.80+164.1%-35.9%$554.18MN/A-2.83116Analyst RevisionHUMAHumacyte2.8364 of 5 stars$4.39-4.8%$13.71+212.4%+70.9%$552.52M$1.57M-3.28150Short Interest ↑Analyst RevisionANNXAnnexon2.3042 of 5 stars$4.94+2.3%$15.80+219.8%-8.7%$526.57MN/A-4.7060Short Interest ↑PHVSPharvaris2.5394 of 5 stars$16.41-7.8%$39.25+139.2%-34.5%$522.49MN/A-5.8630Positive NewsGap DownHigh Trading VolumeKROSKeros Therapeutics3.1844 of 5 stars$12.82-12.0%$75.00+485.0%-79.5%$519.30M$651,000.00-2.46100Analyst ForecastShort Interest ↑News CoverageGap UpHigh Trading VolumeMREOMereo BioPharma Group2.1929 of 5 stars$3.34-5.9%$7.83+134.5%-9.1%$518.19M$1M0.0040RAPPRapport Therapeutics2.2991 of 5 stars$13.97-5.7%$35.00+150.5%N/A$510.97MN/A0.00N/A Related Companies and Tools Related Companies VectivBio Competitors Kura Oncology Competitors Tectonic Therapeutic Competitors CARGO Therapeutics Competitors Humacyte Competitors Annexon Competitors Pharvaris Competitors Keros Therapeutics Competitors Mereo BioPharma Group Competitors Rapport Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TCRX) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredDonald Trump is about to free crypto from its chains …With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
